Pernio after COVID‐19 vaccination

Lopez, Samantha; Vakharia, Paras P.; Vandergriff, Travis; Freeman, Esther E.; Vasquez, Rebecca

doi:10.1111/bjd.20404

Cited by 29 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pernio-like lesions and purpuric eruptions have been reported post-COVID-19 vaccination ( Figure 5 ). Of the 41 cases described in 11 observational studies [ 1 , 2 , 21 , 23 , 24 , 27 , 51 , 52 , 53 , 54 , 55 , 56 ], 25 (61.0%) were associated with BNT162b2, 9 (22.0%) with ADZ1222, and 7 (17.1%) with mRNA-1273 vaccination ( Table 1 ). In a series of 16 patients, purpuric manifestations appeared at a mean of 7.6 days after COVID-19 vaccination and lasted a mean of 15.7 days [ 2 ].…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Vascular dysregulation that derives from both cytokine overactivation and environmental factors is supposedly responsible for ChLE [41]. Recently, rapid onset of chilblains has also been described in the course of mRNA vaccines [47]; this vaccine-derived phenomenon is currently believed to resemble a mimic of the natural immune response to SARS-CoV-2 that also shows similarity to ChLE [21,48]. When compared to mRNA vaccines and vector vaccines, inactivated viral vaccines represent poor inducers of cytotoxic CD8+ T cells [2].…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

et al. 2021

View full text Add to dashboard Cite

(1) Background: Numerous vaccines are under preclinical and clinical development for prevention of severe course and lethal outcome of coronavirus disease 2019 (COVID-19). In light of high efficacy rates and satisfactory safety profiles, some agents have already reached approval and are now distributed worldwide, with varying availability. Real-world data on cutaneous adverse drug reactions (ADRs) remain limited. (2) Methods: We performed a literature research concerning cutaneous ADRs to different COVID-19 vaccines, and incorporated our own experiences. (3) Results: Injection site reactions are the most frequent side effects arising from all vaccine types. Moreover, delayed cutaneous ADRs may occur after several days, either as a primary manifestation or as a flare of a pre-existing inflammatory dermatosis. Cutaneous ADRs may be divided according to their cytokine profile, based on the preponderance of specific T-cell subsets (i.e., Th1, Th2, Th17/22, Tregs). Specific cutaneous ADRs mimic immunogenic reactions to the natural infection with SARS-CoV-2, which is associated with an abundance of type I interferons. (4) Conclusions: Further studies are required in order to determine the best suitable vaccine type for individual groups of patients, including patients suffering from chronic inflammatory dermatoses.

show abstract

“…

…”

mentioning

confidence: 99%

“…1,2 Commonly observed cutaneous reactions include local injection-site erythema or discomfort, as well as urticarial and morbilliform eruptions. [1][2][3] Less frequent sequalae include perniosis, herpes simplex virus reactivation, flares of psoriasis, and pityriasis rosea-like reactions. 1,4 We report a 66-year-old female with hypertension, hypothyroidism, and hypercholesterolemia, who developed firm, tender, 4-5 cm deep-seated nodules on the right superior medial popliteal fossa and bilateral anterior tibia, 10 days after receiving the first dose of the COVID-19 Moderna mRNA-1273 vaccine (Figure 1).…”

mentioning

confidence: 99%

Erythema nodosum after Moderna mRNA ‐1273 COVID‐19 vaccine

Teymour

Ahram

Blackwell

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Since the emergence of mRNA COVID-19 vaccines, various secondary cutaneous reactions have been reported. 1,2 Commonly observed cutaneous reactions include local injection-site erythema or discomfort, as well as urticarial and morbilliform eruptions. [1][2][3] Less frequent sequalae include perniosis, herpes simplex virus reactivation, flares of psoriasis, and pityriasis rosea-like reactions. 1,4 We report a 66-year-old female with hypertension, hypothyroidism, and hypercholesterolemia, who developed firm, tender, 4-5 cm deep-seated nodules on the right superior medial popliteal fossa and bilateral anterior tibia, 10 days after receiving the first dose of the COVID-19 Moderna mRNA-1273 vaccine (Figure 1). The patient provided informed consent to publish this case. By the time of medical evaluation, some nodules had begun to fade, and the patient was otherwise well, without symptoms of COVID-19 infection. The clinical impression was erythema nodosum (EN), and incisional biopsy of the nodule at the right superior medial popliteal fossa was performed 3 days later. One day prior to biopsy, COVID-19 PCR nasopharyngeal testing was negative. Histologic sections demonstrated widened subcutaneous septae containing an inflammatory infiltrate of lymphocytes, neutrophils, eosinophils, and histiocytes, compatible with EN. Routine hematologic and chemistry studies were unremarkable.Erythrocyte sedimentation rate, C-reactive protein, and circulating rheumatoid factor were normal. Anti-nuclear antibodies, anti-doublestranded DNA antibodies, anti-streptolysin antibodies, and hepatitis B

show abstract

Pernio after COVID‐19 vaccination

Cited by 29 publications

References 8 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

Erythema nodosum after Moderna mRNA ‐1273 COVID‐19 vaccine

Contact Info

Product

Resources

About